Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NEK7 | Q8TDX7 | 18/20 | 0.56 |
| ▸ | EGFR | P00533 | 2/20 | 0.51 |
| ▸ | SRC | P12931 | 2/20 | 0.51 |
| ▸ | ABL1 | P00519 | 1/20 | 0.51 |
| ▸ | ABL2 | P42684 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | RGS12 | O14924 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | GMNN | O75496 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | LCK | P06239 | 1/20 | 0.50 |
| ▸ | FYN | P06241 | 1/20 | 0.50 |
| ▸ | LYN | P07948 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23966929 | 0.91 | NEK7 (0.64) | NEK7SRC | |
| SCHEMBL29484486 | 0.91 | NEK7 (0.64) | NEK7SRC | |
| SCHEMBL27088000 | 0.89 | NEK7 (0.64) | NEK7TEK | |
| SCHEMBL29175943 | 0.82 | RIPK2 (0.53) | NEK7EGFRSRCABL1ABL2 | |
| SCHEMBL29998985 | 0.81 | KDR (0.59) | EGFRSRCKDM4EMEN1RGS12 | |
| SCHEMBL25793334 | 0.81 | EIF2AK3 (0.51) | NEK7 | |
| SCHEMBL29998803 | 0.81 | EIF2AK3 (0.51) | NEK7 | |
| SCHEMBL29998976 | 0.81 | RIPK2 (0.71) | NEK7EGFRSRCABL1ABL2 | |
| SCHEMBL29175947 | 0.81 | RIPK2 (0.71) | NEK7EGFRSRCABL1ABL2 | |
| SCHEMBL2074654 | 0.80 | IGF1R (0.60) | NEK7EGFRSRCABL1ABL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240317758-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. | 2024-09-26 | — | — | US | disclosed |
| EP-4320127-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| WO-2022216680-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. (US) | 2022-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317758-A1 | NEK7 INHIBITORS | NEK7, NEK5, NEK1 | NEK7 1/4885EGFR 4852/4885SRC 1649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.